Abstract
Abbreviations ADC Apparent diffusion coefficient DWI Diffusion-weighted magnetic resonance imaging EPI Echo-planar imaging FOV Field of view MRI Magnetic resonance imaging ROI Region of interest TE Time to echo TR Repetition time Diffusion-weighted magnetic resonance imaging (DWI) has become an integral part of oncologic imaging studies to aid in the detection and diagnosis of solid tumors. While regions of reduced extracellular space due to increased cell density will result in restricted diffusion of mobile proton species, disruptions in cellular integrity as attributable to apoptosis may lead to an increase in free-water molecule motion. Consequently, the most applied quantitative parameter for describing tissue diffusivity, the apparent diffusion coefficient (ADC), has been widely investigated as a prognostic biomarker for response assessment to anti-cancer therapy [1] . However, despite its value in diagnosing and monitoring of disease, there is some controversy in the literature regarding the limited reproducibility of ADC estimates across different imaging platforms and imaging sites. This is mainly because variations in acquisition parameters across scanners from different vendors and between models from the same manufacturer can widely affect ADC quantitation. Previous studies investigated ADC estimates in the abdominal organs of DWI data sets from healthy volunteers imaged on scanners from different vendors at 1.5 and 3 T in order to determine the extent of ADC variability. Among others, two of these multi-center studies found poor agreement in the pancreas and kidneys at 3 T and poor agreement particularly in the liver at both field strengths [2, 3] . The DWI parameter settings were kept constant across imagers to the maximum possible extent; as such, the same echo-planar imaging (EPI) sequence, field of view (FOV), matrix size, number of averages, slice thickness, and interslice gap were set identically in all scanners. However, the TE, TR, b-values, and methods of parallel imaging could not be completely standardized across platforms-although the preset contained the same subset of bvalues for subsequent acquisition. Another multi-center study focusing on gray and white matter in healthy volunteers also showed significant variations in ADC estimates between scanners from the same vendor and between scanners from different manufacturers; again, TE, TR, and methods of parallel imaging could not be fully standardized [4] . Hence, timing parameters and methods of parallel imaging were shown to be inconsistent despite effective protocol standardization, demonstrating the difficulty of producing fully standardized DWI protocols across different imaging platforms and sites. This lack of standardization of ADC measurement is a serious limitation to this quantitative parameter to be a reliable imaging biomarker.
In oncologic imaging studies, ADC reproducibility further depends on various critical factors including the tumor pathophysiology itself [5] , curve-fitting techniques [6] , and system stability [7] . Voxel-wise ADC quantification in the liver is also specifically degraded by respiratory motion artifacts, with as little or no improvement despite utilization of compensation methods such as navigator echo and respiratory gating [8] . The common lack of agreement in ADC estimates of the liver may also depend on the lower signal compared with other organs, owing to the short T2 decay, eventually leading to greater sensitivity to the noise characteristics of different MR imagers. Another more practical but not insubstantial source of error in ADC quantitation is the choice of delineation methods for region of interest (ROI) selection; even small variations in the ROI geometry and its position can substantially influence tumor ADC measurements and thus affect sensitivity to changes in tumoral ADC values [9] . Similarly, therapy-induced changes in tumor vascularization or peritumoral tissue density may affect the depiction and thus reproducibility of ROI delineation. Current consensus guidelines for DWI as a cancer biomarker recommend delineation of 3D whole tumor volumes that are more reproducible than single-slice measurements but require substantially more examination time [1] . Automated methods which may provide improved accuracy could remedy this situation but would require the highest possible image quality to accurately delineate tumor boundaries. Since abdominal DWI is regularly subject to physiological motion, this would probably necessitate regular manual interventions which query the concept of using a fully automated ROI application scheme as an add-on technique.
Summarizing the above, it appears that multi-centric and multi-device studies, highly desirable in any case, are almost always subject to measurement bias and therefore difficult to establish. Therefore, the question we are facing is how to overcome the present impasse? A possible consensus that might apply to therapy response assessment could be comparative analysis of the percentage difference between pre-and post-treatment ADC values obtained from the same scanner, rather than focusing on absolute ADC values alone. Alternatively, normalization of ADC values by calculating the ratio of the investigated organ to a reference organ could help reducing the limits of expected bias. Given that the variety of described confounders will be identified and widely corrected prior to the calculation of parametric images, this could facilitate consistent use of ADC as an imaging biomarker for multi-center or longitudinal studies if absolute ADC values are not directly comparable between imagers. However, this still remains to be verified by larger and particularly patient studies, and major efforts need to continue to enhance protocol standardization.
Recently, a rather mathematically oriented study pursued a statistical approach to minimize ADC variability across four imaging sites with scanners from different vendors by implementing a post hoc correction model to already calculated parametric DW images [10] . The primary endpoint of this study was to define a statistical model of predictable sources of variability that contribute to measurement error (also including data sets with visible motion artifacts) and fit this to observed data in order to quantify the level of uncertainty in mean ADC repeatability. By application of the proposed model, the 95% confidence interval width used to determine a statistically significant ADC change in 20 patients with colorectal cancer liver metastases reduced from 21.1 to 2.7% after standardization. According to the authors, implementation of the proposed model will allow significant improvements in sensitivity for detection of change in ADC. They provided a lookup chart to allow investigators to estimate uncertainty due to statistical measurement error, for any given tumor volume and ADC histogram width [10] . This model may help to assess reproducibility with greater confidence, and could also be easily implemented into clinical routine.
Funding The author states that this work has not received any funding.
Compliance with ethical standards
Guarantor The scientific guarantor of this publication is Dr. med. Frederic Carsten Schmeel at Bonn University Hospital.
Conflict of interest
The author declares that he has no conflict of interest.
Statistics and biometry No complex statistical methods were necessary for this paper.
Informed consent Written informed consent was not required for this study because this is not a study but an editorial comment.
Ethical approval Institutional Review Board approval was not required for this study because this is not a study but an editorial comment.
Methodology
• Observational
